Fox Chase Cancer Center and Arima Genomics, Inc. have launched a first-of-its-kind partnership aimed at bringing advanced ...
SAN DIEGO--(BUSINESS WIRE)--Arima Genomics, Inc., the leader in 3D genomics, today announced the close of its $7 million Series B Preferred Stock financing round. New investors Genetron Health (NASDAQ ...
13d
Fox Chase Cancer Center and Arima Genomics Partner to Advance 3D Genome Diagnostics for Cancer Care
Fox Chase Cancer Center and Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that ...
Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced that the Aventa™ Lymphoma test ...
The ARIMA statement applies the X-11-ARIMA method to the series specified in the VAR statement. This method uses an ARIMA model estimated from the original data to extend the series one or more years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback